| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1963) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | N05BA01 |
| UNII: | Q3JTX2Q7TU |
Structure
| InChI Key | AAOVKJBEBIDNHE-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C16H13ClN2O |
| Molecular Weight | 284.75 |
| AlogP | 3.15 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 1.0 |
| Polar Surface Area | 32.67 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 20.0 |
Experimental and Estimated Properties
| Property Name | Value | Unit | Method |
|---|---|---|---|
| log P (octanol-water) | 2.82 | - | EXP |
| pKa Dissociation Constant | 3.4 | - | EXP |
| Henry's Law Constant | 3.64E-09 | atm-m3/mole | EST |
| Atmospheric OH Rate Constant | 9.90E-12 | cm3/molecule-sec | EST |
| Melting Point | 132 | deg C | EXP |
| Water Solubility | 50 | mg/L | EXP |
| Vapor Pressure | 2.78E-08 | mm Hg | EST |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| POSITIVE ALLOSTERIC MODULATOR | GABA-A receptor; anion channel positive allosteric modulator |
| Primary Target | |
|---|---|
| GABAA receptor α1 subunit | |
| GABAA receptor α2 subunit | |
| GABAA receptor α3 subunit |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Vertigo | 3 | D014717 | ClinicalTrials |
| Seizures | 3 | D012640 | ClinicalTrials |
| Pain | 3 | D010146 | ClinicalTrials |
| Dementia | 3 | D003704 | ClinicalTrials |
| Status Epilepticus | 3 | D013226 | ClinicalTrials |
| Epilepsy, Complex Partial | 3 | D017029 | ClinicalTrials |
| Depressive Disorder | 3 | D003866 | ClinicalTrials |
| Schizophrenia | 3 | D012559 | ClinicalTrials |
| Rotator Cuff Injuries | 2 | D000070636 | ClinicalTrials |
| Wounds and Injuries | 2 | D014947 | ClinicalTrials |
| Landau-Kleffner Syndrome | 2 | D018887 | ClinicalTrials |
| Low Back Pain | 2 | D017116 | ClinicalTrials |
Related Entries
MCS
Scaffolds
Side Effects from Label
Side Effects (PT)
| Side effects | Relative Frequency (%) | Labels | |
|---|---|---|---|
| Nervous system disorders Somnolence | 23.0 | ||
| Nervous system disorders Ataxia | 8.0 | ||
| General disorders and administration site conditions Asthenia | 4.0 | ||
| Gastrointestinal disorders Hiccups | 2.0 | ||
| Ear and labyrinth disorders Vertigo | 2.0 |
Adverse Reactions
System Organ Classification (SOC)
Environmental Impact
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 439-14-5 |
| ChEBI | 49575 |
| ChEMBL | CHEMBL12 |
| DrugBank | DB00829 |
| DrugCentral | 852 |
| EPA CompTox | DTXSID4020406 |
| FDA SRS | Q3JTX2Q7TU |
| Human Metabolome Database | HMDB14967 |
| Guide to Pharmacology | 3364 |
| KEGG | C06948 |
| PDB | DZP |
| PharmGKB | PA449283 |
| PubChem | 3016 |
| SureChEMBL | SCHEMBL21442 |
| ZINC | ZINC000000006427 |
CONTENTS